可溶性白细胞介素-2受体——上呼吸道消化道鳞状细胞癌的一个标志物。

The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.

作者信息

Gottschlich S, Görögh T, Lippert B M, Niemann A M, Folz B J, Werner J A

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Germany.

出版信息

Anticancer Res. 1997 Jul-Aug;17(4B):2921-2.

PMID:9329564

Abstract

Various studies indicate that the soluble interleukin-2 receptor (sIL-2R) is of value as marker in chronic and malignant disorders. No data are available on sIL-2R levels in head and neck cancer. The serum of 86 patients with squamous cell carcinoma of the head and neck (SCCHN) prior to any therapy and of 25 healthy controls was taken. Six month later the serum of 49 patients was taken again. sIL-2R levels were determined with ELISA. Patients with SCCHN prior to therapy had significantly elevated sIL-2R serum levels (895 U/ml) compared to controls (437 U/ml). After an eight month follow up 78.4% of the SCCHN patients with tumor recurrence had increased and 80% of the carcinoma patients without recurrence had decreased sIL-2R levels compared to prior to therapy. sIL-2R seems to be an unspecific marker for SCCHN and may be of prognostic value.

摘要

多项研究表明，可溶性白细胞介素-2受体（sIL-2R）作为慢性和恶性疾病的标志物具有一定价值。目前尚无关于头颈部癌患者sIL-2R水平的数据。采集了86例未经任何治疗的头颈部鳞状细胞癌（SCCHN）患者及25例健康对照者的血清。6个月后再次采集了49例患者的血清。采用酶联免疫吸附测定法（ELISA）测定sIL-2R水平。与对照组（437 U/ml）相比，未经治疗的SCCHN患者血清sIL-2R水平显著升高（895 U/ml）。经过8个月的随访，与治疗前相比，肿瘤复发的SCCHN患者中有78.4%的sIL-2R水平升高，未复发的癌患者中有80%的sIL-2R水平降低。sIL-2R似乎是SCCHN的一种非特异性标志物，可能具有预后价值。